Journal
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
Volume 55, Issue 6, Pages 456-468Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jaac.2016.03.012
Keywords
antipsychotic; child; adolescent; autism; intellectual disability
Categories
Funding
- National Institute on Drug Abuse
- National Institute of Mental Health (NIMH)
- Patient-Centered Outcomes Research Institute (PCORI)
- Agency for Healthcare Research and Quality
- Sunovion Pharmaceuticals
- Johnson and Johnson
- NIMH
- PCORI
- American Academy of Child and Adolescent Psychiatry
- Bendheim Foundation
- Takeda
- Thrasher Foundation
Ask authors/readers for more resources
Objective: Although irritability and aggression are relevant treatment targets in autism spectrum disorders (ASDs) and intellectual disability (ID) that may prompt antipsychotic use, antipsychotic prescribing patterns in such youth have not been systematically reviewed. Method: We systematically searched PubMed/MEDLINE/PsycInfo until March 2015 for studies reporting data on the frequency of youth diagnosed with ASDs and/or ID among antipsychotic-treated youth, as well as antipsychotic use in youth with ASD/ID, conducting a meta-analysis and meta-regression analysis of potential moderators, including publication year, study time point, country, setting, sample size, age, sex, and race/ethnicity. Results: A total of 39 studies were meta-analyzed (n = 365,449, age = 11.4 +/- 6.2 years, males = 70.0%+/- 10.0%). Among 27 studies (n = 273,139, age = 11.9 +/- 8.0 years, males = 67.0%+/- 12.9%) reporting on antipsychotictreated youth, 9.5% (95% CI = 7.8%-11.5%) were diagnosed with ASD/ID. In 20 studies (n = 209,756) reporting data separately for ASD, 7.9% (95% CI = 6.2%-9.9%) had an ASD diagnosis. In 5 longitudinal studies, the proportion of antipsychotic-treated youth with ASD did not change significantly from 1996 to 2011 (6.7% to 5.8%, odds ratio = 0.9, 95% CI = 0.8-1.0, p =.17). However, later study time point moderated greater ASD/ID proportions (beta = 0.12, p <.00001). In 13 studies (n = 96,688, age = 9.8 +/- 1.2 years, males = 78.6%+/- 2.0%) reporting on antipsychotic use in ASD samples, 17.5% (95% CI = 13.7%-22.1%) received antipsychotics. Again, later study time point moderated higher antipsychotic use among patients with ASD (beta = 0.10, p =.004). Conclusion: Almost 1 in 10 antipsychotic-treated youth were diagnosed with ASD and/or ID, and 1 in 6 youth with ASD received antipsychotics. Both proportions increased in later years; however, clinical reasons and outcomes of antipsychotic use in ASD/ID require further study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available